Spratt Kelly Anne
University of Pennsylvania Health System, Cardiovascular Division, Philadelphia Heart Institute, Second Floor, 39th & Market Streets, Philadelphia, PA 19104, USA.
J Am Osteopath Assoc. 2004 Sep;104(9 Suppl 7):S9-13.
Elevated low-density lipoprotein cholesterol (LDL-C) is closely associated with an increased risk of cardiovascular morbidity and mortality. Results from numerous well-designed clinical trials indicate that interventions designed to modify lipid levels significantly reduce the risk of coronary heart disease (CHD), particularly in patients at highest risk. The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines recommend matching the intensity of lipid-lowering therapy to the patient's risk of CHD. However, despite the existence of evidence-based treatment guidelines and the availability of many safe and effective lipid-modifying modes of therapy, optimal CHD risk reduction rarely is achieved.
低密度脂蛋白胆固醇（LDL-C）升高与心血管疾病发病率和死亡率增加密切相关。众多精心设计的临床试验结果表明，旨在改变血脂水平的干预措施可显著降低冠心病（CHD）风险，尤其是在高危患者中。美国国家胆固醇教育计划（NCEP）成人治疗专家组第三次报告（ATP III）指南建议，降脂治疗的强度应与患者的冠心病风险相匹配。然而，尽管有循证治疗指南，且有多种安全有效的调脂治疗方式可供选择，但很少能实现最佳的冠心病风险降低效果。
